Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review highlights the potential of targeting the natriuretic peptide receptor A (NPRA) signaling pathway for the treatment of allergic diseases such as asthma.
Atrial natriuretic peptide (ANP), the C-terminal peptide comprising residues 99-126 of the pro-ANP hormone, has been studied for 3 decades for its cardiovascular effects. Recent reports suggest that it plays a significant role in modulation of the immune system. Immune cells, including macrophages, dendritic cells, and T lymphocytes, express receptors for ANP. ANP plays a significant role in shaping the early immune response to environmental antigens and may play a critical role in the interaction between cells of the innate and adaptive immune systems; it also appears to be involved in polarizing the immune response to allergens. Thus, ability to alter the magnitude of natriuretic peptide receptor A (NPRA) signaling could be exploited to develop therapeutics for several allergic diseases, including asthma. This report will review and critically evaluate the role of the ANP pathway in asthma and inflammation.
No takes yet. Share an insight, caveat, or question.
Shyam S. Mohapatra (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: